2% Lignocaine Viscous Gargle Versus Intravenous Lignocaine as Adjuvants to Propofol for Laryngeal Mask Airway Insertion: A Prospective, Randomised, Single-Blinded Clinical Trial
International Journal of Current Pharmaceutical Review and Research · 31.05.2026 · 18 (05)
DOI: 10.25258/ijcpr.18.5.73 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.05.2026. Verfasst von Neha Aeron und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Both intravenous (IV) lignocaine and 2% viscous lignocaine gargle are used as adjuvants to suppress airway reflexes during laryngeal mask airway (LMA) insertion; however, direct comparative evidence is limited.
Methods
In this prospective, randomised, single-blinded clinical trial, 60 ASA I–II patients undergoing elective short-duration procedures were randomised to Group A (IV lignocaine 1.5 mg/kg, 90 seconds before LMA insertion, n = 30) or Group B (2% viscous lignocaine gargle 20 mL for 30 seconds, 6 minutes before induction, n = 30). All patients received propofol 2 mg/kg and fentanyl 2 mcg/kg for induction. Primary outcomes were coughing, gagging, and laryngospasm during LMA insertion. Secondary outcomes included insertion attempts, insertion time, ease of insertion, and haemodynamic (HR, SBP, DBP, MAP, SpO2) recorded at pre-specified intervals over 30 minutes. Data were analysed using Student's t-test, chi-square test, and Fisher's exact test; p < 0.05 was considered statistically significant.
Results
Both groups were demographically comparable at baseline (p > 0.05 for all). Primary outcomes – coughing (p = 0.085), gagging (p = 0.224), and laryngospasm (p = 0.313) – showed numerically lower event rates in Group B but without statistical significance. Insertion attempts, time, and ease were comparable (p > 0.2 for all). Group A demonstrated significantly elevated HR, SBP, DBP, and MAP during the first 0–4 minutes postinsertion (p < 0.05), converging with Group B from 5 minutes onward. SpO2 remained within normal limits in both groups throughout. No postoperative complications were recorded in either group.
Conclusion
Both adjuvants achieve comparable LMA insertion conditions. Viscous lignocaine gargle confers superior early haemodynamic stability and a clinically relevant reduction in adverse airway events, supporting its consideration as a preferred, non-invasive alternative to IV lignocaine for LMA insertion facilitation.
Zitieren
APA
Aeron, N., Mantan, K., Desai, S., Kataria, V., & Janu, S. (2026). 2% Lignocaine Viscous Gargle Versus Intravenous Lignocaine as Adjuvants to Propofol for Laryngeal Mask Airway Insertion: A Prospective, Randomised, Single-Blinded Clinical Trial. International Journal of Current Pharmaceutical Review and Research, 18(05). https://doi.org/10.25258/ijcpr.18.5.73
Vancouver
Aeron N, Mantan K, Desai S, Kataria V, Janu S. 2% Lignocaine Viscous Gargle Versus Intravenous Lignocaine as Adjuvants to Propofol for Laryngeal Mask Airway Insertion: A Prospective, Randomised, Single-Blinded Clinical Trial. International Journal of Current Pharmaceutical Review and Research. 2026;18(05). doi:10.25258/ijcpr.18.5.73
BibTeX
@article{Aeron2026,
author = {Aeron, Neha and Mantan, Kiwi and Desai, Sachin and Kataria, Vanshika and Janu, Shubham},
title = {2% Lignocaine Viscous Gargle Versus Intravenous Lignocaine as Adjuvants to Propofol for Laryngeal Mask Airway Insertion: A Prospective, Randomised, Single-Blinded Clinical Trial},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {05},
doi = {10.25258/ijcpr.18.5.73}
}
EUVIMED